A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00391729
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
221
Enrollment
INDUSTRY
Sponsor class
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
DRUG:
ABT-089
DRUG:
Placebo
Sponsor
Abbott